Ask AI
ProCE Banner Activity

An Expert’s Guide to ESMO 2025: A Preview of the Top Abstracts

Conference Coverage
Clinical Thought

Experts highlight their choice of key studies being presented at the 2025 ESMO Annual Meeting. CCO’s Independent Conference Coverage includes timely summaries, expert analysis, and practical implications of the latest research and developments in oncology to help you stay at the forefront of advances in cancer care.

Released: October 16, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly

Disclosure

Primary Author

Luis Paz-Ares, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Bayer, BeOne, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GSK, Janssen, Lilly, Merck KGaA, Mirati, MSD, Novartis, Pfizer, PharmaMar, Regeneron, Roche, Takeda; board of directors: Altum Sequencing, Stab Therapeutics.

David Planchard, MD, PhD: consultant/advisor/speaker: AbbVie, ArriVent, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Daiichi Sankyo, GSK, Janssen, Lilly, Merck, Mirati, Novartis, Pfizer, Pierre-Fabre, Roche, Seagen, Takeda.

Cristina Saura Manich, MD, PhD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, F. Hoffmann-La Roche, Gilead, Lilly, Menarini, MSD, Novartis, Pfizer, Philips, Puma, Relay Therapeutics, Sanofi, Zymeworks.

Paolo Tarantino, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Gilead, Lilly, Menarini/Stemline, Novartis.